Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EGFR Antibody with IMRT and Chemotherapy in Induction-Resistant Oropharyngeal Carcinoma
NCT04508829Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2016
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and nimotuzumab in oropharyngeal carcinoma (OPC), sponsored by Fudan University. Primary endpoints: Progression-Free Survival at 3 years and Adverse Events Rate. Status: unknown.
02
Drugs
cetuximabnimotuzumab
03
Conditions
oropharyngeal carcinoma (OPC)
Beyond the preview
Go deeper on NCT04508829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508829.